Group 1 - The core viewpoint of the article is that Guosen Securities has given a "better than market" rating to Aimeike (300896.SZ) based on recent developments in its product pipeline and market potential [1] - Aimeike's exclusive distribution of Huons BioPharma's injectable botulinum toxin product has received regulatory approval for sale in China, including Hong Kong and Macau, filling a gap in its product line [1] - The company is expected to enhance its core competitiveness by offering comprehensive solutions through the combination of new and existing products, with ongoing research and development in weight management and submental fat products [1] Group 2 - The medical aesthetics consumption penetration rate still has significant room for improvement, indicating potential growth opportunities for the industry [1] - Aimeike is investing in self-research to develop new product lines while also pursuing mergers and acquisitions to enrich its product pipeline and expand international business [1] - The company’s performance growth is supported by these strategies, although there are potential risks related to project progress and market competition [1]

Core Viewpoint - The overall performance in Q3 is under pressure, with revenue of 566 million yuan, a year-on-year decrease of 21.27%, and a net profit attributable to shareholders of 304 million yuan, down 34.61% year-on-year [1] - The first three quarters show a revenue decline of 21.49% year-on-year and a net profit decrease of 31.05% year-on-year, attributed to consumer spending pressure and intensified competition in the medical aesthetics industry [1] Financial Performance - The gross margin for Q3 is 93.19%, a decline of 1.36 percentage points year-on-year, influenced by changes in product structure and increased industry competition [1] - The expense ratios are as follows: selling expense ratio at 15.37% (up 6.39 percentage points), management expense ratio at 8.82% (up 5.51 percentage points), and R&D expense ratio at 14.3% (up 5.72 percentage points), reflecting rigid expenses and declining revenue [1] - Operating cash flow for the first three quarters is 1.073 billion yuan, a decrease of 30.12% year-on-year, due to the decline in net profit and changes in working capital [1] Product Development and Market Outlook - The company is in a transitional phase with its product line, facing weakened demand for traditional medical aesthetic products, while focusing on the development of new products such as botulinum toxin and weight loss solutions [1] - Despite current challenges, there is significant potential for growth in medical aesthetic consumption penetration in the medium to long term [2]

Investment Rating - The investment rating for the company is "Outperform the Market" [3][5][12] Core Views - The company's overall performance in Q3 2025 was under pressure, with revenue of 566 million yuan, a year-on-year decrease of 21.27%, and a net profit attributable to shareholders of 304 million yuan, down 34.61% year-on-year. The first three quarters saw a revenue decline of 21.49% and a net profit drop of 31.05% [2][3] - The decline in performance is attributed to ongoing consumer spending pressures and intensified competition in the medical beauty industry. Additionally, the company is in a transitional phase with its product line, as traditional medical beauty products are experiencing weakened demand. Future focus will be on the development of new medical beauty products such as botulinum toxin and weight loss solutions [2][3] - The gross profit margin for Q3 2025 was 93.19%, a decrease of 1.36 percentage points year-on-year, influenced by changes in product structure and increased industry competition. The company has maintained a commitment to R&D, with R&D expenses rising by 5.72% year-on-year to 14.3% of revenue [2][3] - The company has adjusted its net profit forecasts for 2025-2027 to 1.564 billion, 1.794 billion, and 2.099 billion yuan, respectively, reflecting a decrease from previous estimates. The corresponding price-to-earnings ratios are projected to be 31.6, 27.5, and 23.5 times [3][12] Financial Summary - For 2025, the company is expected to generate revenue of 2.598 billion yuan, a decrease of 14.13% year-on-year, with a net profit of 1.564 billion yuan, down 20.10% year-on-year. The earnings per share are projected to be 5.18 yuan [4][14] - The company's EBIT margin is forecasted to be 68.37% for 2025, with a return on equity (ROE) of 17.86% [4][14] - The company’s cash flow from operations for the first three quarters was 1.073 billion yuan, a decrease of 30.12% year-on-year, primarily due to the decline in net profit and changes in working capital [2][3]